Carcinoma

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Tuesday, June 30, 2020 - 11:45pm

For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.

Key Points: 
  • For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
  • BAVENCIO (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
  • In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
  • A fatal adverse reaction (sepsis) occurred in one (0.3%) patient with locally advanced or metastatic urothelial carcinoma (UC) receiving BAVENCIOplus best supportive care (BSC) as first-line maintenance treatment.

Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

Monday, June 29, 2020 - 1:30pm

Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

Key Points: 
  • Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.
  • Dr. Aivado explained, Chemotherapy remains a critical cornerstone treatment for millions of cancer patients.
  • We treat healthy cells ahead of chemotherapy to prevent those toxicities, importantly, without interrupting chemotherapys potent onslaught against cancer cells.
  • There are two parts to the Phase 1b study: (i) dose optimization and (ii) schedule optimization.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation

Wednesday, June 24, 2020 - 10:29pm

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

Key Points: 
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
  • KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

United States Renal Cell Carcinoma Market and Competitive Landscape 2016-2025 - ResearchAndMarkets.com

Wednesday, June 17, 2020 - 12:26pm

The "US Renal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Renal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into Renal Cell Carcinoma pipeline products, Renal Cell Carcinoma epidemiology, Renal Cell Carcinoma market valuations and forecast, Renal Cell Carcinoma drugs sales and competitive landscape in the US.
  • Renal Cell Carcinoma pipeline: Find out the products in clinical trials for the treatment of Renal Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Renal Cell Carcinoma drugs: Identify key products marketed and prescribed for Renal Cell Carcinoma in the US, including trade name, molecule name, and company
    Renal Cell Carcinoma drugs sales: Find out the sales revenues of Renal Cell Carcinoma drugs in the US
    Renal Cell Carcinoma market valuations: Find out the market size for Renal Cell Carcinoma drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Renal Cell Carcinoma drugs market share: Find out the market shares for key Renal Cell Carcinoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Renal Cell Carcinoma products
    1.

Global Squamous Cell Carcinoma Market Insights, 2016-2024 - ResearchAndMarkets.com

Wednesday, June 17, 2020 - 9:54am

The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Squamous Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Squamous Cell Carcinoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The report covers the following: Squamous Cell Carcinoma treatment options, Squamous Cell Carcinoma late stage clinical trials pipeline, Squamous Cell Carcinoma prevalence by countries, Squamous Cell Carcinoma market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Squamous Cell Carcinoma pipeline: Find out drugs in clinical trials for the treatment of Squamous Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Squamous Cell Carcinoma drugs: Identify key drugs marketed and prescribed for Squamous Cell Carcinoma in the US, including trade name, molecule name, and company
    Squamous Cell Carcinoma drugs sales: Find out the sales value for Squamous Cell Carcinoma drugs by countries
    Squamous Cell Carcinoma market valuations: Find out the market size for Squamous Cell Carcinoma drugs in 2019 by countries.

PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca™) for the Treatment of Metastatic Small Cell Lung Cancer

Tuesday, June 16, 2020 - 2:38pm

This approval will allow Jazz to make lurbinectedin (Zepzelca) commercially available in the U.S. in early July.

Key Points: 
  • This approval will allow Jazz to make lurbinectedin (Zepzelca) commercially available in the U.S. in early July.
  • "It is great to see a new therapeutic agent available for patients with relapsed small cell lung cancer!
  • "For decades, effective therapies after initial treatment were nonexistent for people diagnosed with small cell lung cancer," said Jennifer C. King, Ph.D., Chief Scientific Officer of GO2 Foundation for Lung Cancer.
  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma

Tuesday, June 9, 2020 - 9:05pm

KEYNOTE-361 (ClinicalTrials.gov, NCT02853305 ) is a randomized, open-label, Phase 3 trial evaluating KEYTRUDA as monotherapy and in combination with chemotherapy versus chemotherapy alone, the current standard of care, for the first-line treatment of advanced or metastatic urothelial carcinoma.

Key Points: 
  • KEYNOTE-361 (ClinicalTrials.gov, NCT02853305 ) is a randomized, open-label, Phase 3 trial evaluating KEYTRUDA as monotherapy and in combination with chemotherapy versus chemotherapy alone, the current standard of care, for the first-line treatment of advanced or metastatic urothelial carcinoma.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or metastatic urothelial carcinoma.

AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma

Monday, June 1, 2020 - 6:15pm

The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021.

Key Points: 
  • The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021.
  • The FDA also indicated that they do not currently plan on convening an Oncologic Drug Advisory Committee (ODAC) to discuss the application.
  • We look forward to working closely with the FDA over the coming months during their review of our application.
  • AVEO is working to develop and commercialize tivozanib in North America as a treatment for renal cell carcinoma, hepatocellular carcinoma and other cancers.

AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

Friday, May 29, 2020 - 12:05pm

We believe the safety we have seen in Phase 1 of this combination study supports the unique profile that would make tivozanib an attractive VEGF TKI to combine with immunotherapy.

Key Points: 
  • We believe the safety we have seen in Phase 1 of this combination study supports the unique profile that would make tivozanib an attractive VEGF TKI to combine with immunotherapy.
  • The trial is being conducted as part of a clinical collaboration between AVEO and AstraZeneca.
  • AVEO is developing an oncology pipeline designed to provide a better life for patients with cancer.
  • AVEO is working to develop and commercialize tivozanib in North America as a treatment for renal cell carcinoma, hepatocellular carcinoma and other cancers.

Small Cell Lung Cancer (SCLC) Markets in the United States, EU5 and Japan (2017-2030): Epidemiology, Marketed & Emerging Drugs, Unmet Needs, Competitive Landscape - ResearchAndMarkets.com

Tuesday, May 19, 2020 - 11:00am

The Small Cell Lung Cancer epidemiology division provide the insights about historical and current Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries.

Key Points: 
  • The Small Cell Lung Cancer epidemiology division provide the insights about historical and current Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries.
  • Drug chapter segment of the Small Cell Lung Cancer report encloses the detailed analysis of Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • According to the publisher, Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030.
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or Small Cell Lung Cancer market trend.